News & Views

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Germany

News,

Telix today announces that its prostate cancer PET[1] imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Germany by BfArM[2] for the…

Telix’s Illuccix® PSMA-PET Imaging Agent Approved in Portugal

News,

Telix today announces that its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection), has been granted marketing authorization in Portugal by INFARMED for the…

Telix Investor Day in New York City on June 11, 2025: Presenting KOLs

News,

Telix Manufacturing Solutions (TMS) Established in Yokohama, Japan

News,

Telix Highlights ProstACT Global, CUPID and STARLITE Therapy Studies in Prostate and Kidney Cancer at ASCO Annual Meeting 2025

News,

Telix to Host Investor Day in New York City on June 11, 2025

News,

Telix at ANZSNM Annual Scientific Meeting 2025

ASX, News,

Telix Responds to Recent U.S. Government Actions- Most Favored Nation

News,

Telix advises that it has evaluated the Executive Order issued by the United States (U.S.) Government to implement a “Most-Favored Nation” (MFN) policy around drug pricing. Based on currently available…

Illuccix China Phase 3 Study Completes Enrolment

Clinical, News,

Telix today announces that that the pivotal Phase 3 registration study of TLX591-CDx (Illuccix®, Kit for the preparation of 68Ga-PSMA-11) for prostate cancer imaging in Chinese patients has completed patient…

Telix FAP-targeting Therapeutic Published in Thyroid Journal: Demonstrates Encouraging Efficacy

News,

Telix today announces that its Fibroblast Activation Protein (FAP)-targeting therapy candidate, TLX400, has been published in Thyroid, the official journal of the American Thyroid Association. The candidate demonstrated an encouraging…